EUVIMEDEUVIMED entdecken
Crossref

Improving Sorafenib Efficacy in HCC Tumour Cores via PDE5 Inhibitor‐Mediated Vasodilation in Hypoxic Microenvironments: Targeting the Glycolytic Pathway

Vinodinee Dubey iD, Raj Kumar Koiri iD

Journal of Biochemical and Molecular Toxicology · 2025

DOI: 10.1002/jbt.70421 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2025. Verfasst von Vinodinee Dubey und 1 weiteren Autor:innen. Beteiligte Einrichtung: Biochemistry Lab, Department of Zoology, Dr. Harisingh Gour Central University, Sagar, Madhya Pradesh, India. Hauptthemen laut MEDLINE: Sorafenib, Carcinoma, Hepatocellular, Phosphodiesterase 5 Inhibitors, Liver Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 76 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sorafenib is a first‐line treatment for hepatocellular carcinoma (HCC) that inhibits tumour cell proliferation but faces challenges such as modest response rates, side effects, and drug resistance. Ongoing research seeks better treatments and combinations to improve outcomes, which are hindered by drug resistance, inadequate tumour tissue accumulation, and poor penetration. Phosphodiesterase type 5 (PDE5) inhibitors, typically used for erectile dysfunction and pulmonary hypertension, show anticancer potential by relaxing smooth muscle and enhancing blood flow. This study investigates the combination of PDE5 inhibitors, like sildenafil and tadalafil, with sorafenib in an alcohol‐aflatoxin B1‐induced HCC model. The results indicate that this combination enhances the efficacy of sorafenib, increases HCC cell sensitivity, and may help overcome resistance through an ERK‐independent mechanism. The combination therapy not only improves treatment effectiveness but also restores normal cellular functions disrupted by aflatoxin B1 exposure, such as metabolic pathways, glycolysis reduction, and p53 function restoration. Overall, this approach holds promise for overcoming sorafenib resistance in HCC by improving drug accumulation and tumour cell penetration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SorafenibCarcinoma, HepatocellularPhosphodiesterase 5 InhibitorsLiver NeoplasmsGlycolysisTumor MicroenvironmentHumansAnimalsMaleMiceCell Line, TumorSildenafil CitrateTadalafil

Stichwörter der Autor:innen

PDE5iglycolysishepatocellular carcinomasildenafilsorafenibtadalafil

Substanzen

SorafenibPhosphodiesterase 5 InhibitorsSildenafil CitrateTadalafil

Autor:innen und Institutionen

  • Biochemistry Lab, Department of Zoology, Dr. Harisingh Gour Central University, Sagar, Madhya Pradesh, India.

ORCID-Profile: Vinodinee Dubey, Raj Kumar Koiri

Zitieren

APA

Dubey, V., & Koiri, R. K. (2025). Improving Sorafenib Efficacy in HCC Tumour Cores via PDE5 Inhibitor‐Mediated Vasodilation in Hypoxic Microenvironments: Targeting the Glycolytic Pathway. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.70421

Vancouver

Dubey V, Koiri RK. Improving Sorafenib Efficacy in HCC Tumour Cores via PDE5 Inhibitor‐Mediated Vasodilation in Hypoxic Microenvironments: Targeting the Glycolytic Pathway. Journal of Biochemical and Molecular Toxicology. 2025. doi:10.1002/jbt.70421

BibTeX
@article{Dubey2025,
  author = {Dubey, Vinodinee and Koiri, Raj Kumar},
  title = {Improving Sorafenib Efficacy in HCC Tumour Cores via PDE5 Inhibitor‐Mediated Vasodilation in Hypoxic Microenvironments: Targeting the Glycolytic Pathway},
  journal = {Journal of Biochemical and Molecular Toxicology},
  year = {2025},
  doi = {10.1002/jbt.70421}
}
Kostenlos starten →